|
Dr. Clifford Steer is a Professor of Medicine and Genetics, Cell Biology, and Development, and Director of the Molecular Gastroenterology program at the University of Minnesota Medical School. He was trained as a hepatologist at the NIH and remained there for 14 years. During that time, his research focused almost entirely on membrane structure, receptor-mediated endocytosis and intracellular trafficking of proteins. Dr. Steer has published a number of articles in the areas of glycoprotein receptors, receptor recycling, and the role of clathrin and coated vesicles in endocytosis. In addition, he is also widely recognized for his research on mRNA stability and the genetic regulation of liver regeneration. Cliff has been a member of the Scientific Advisory Board for several companies including ValiGen and Vitagen. Dr. Steer’s current research activities focus on gene therapy, gene repair, liver regeneration and apoptosis. His laboratory has recently discovered that the bile acid ursodeoxycholic acid is a potent anti-apoptotic agent, and could potentially be used in the treatment of a variety of disorders, including acute stroke and neurodegenerative diseases. Dr. Steer is an Associate Editor of Hepatology and a member of a newly formed NIH Study Section dedicated only to liver. His research is funded primarily by the NIH. | 